Your browser is no longer supported. Please, upgrade your browser.
GKOS Glaukos Corporation daily Stock Chart
Glaukos Corporation
Index- P/E- EPS (ttm)-1.82 Insider Own0.90% Shs Outstand44.71M Perf Week-0.81%
Market Cap3.16B Forward P/E- EPS next Y-1.08 Insider Trans-32.54% Shs Float43.59M Perf Month10.96%
Income-73.10M PEG- EPS next Q-0.28 Inst Own- Short Float13.13% Perf Quarter49.04%
Sales217.60M P/S14.52 EPS this Y202.20% Inst Trans5.67% Short Ratio9.85 Perf Half Y69.57%
Book/sh14.80 P/B4.47 EPS next Y21.70% ROA-8.20% Target Price55.89 Perf Year4.46%
Cash/sh8.13 P/C8.13 EPS next 5Y8.00% ROE-11.10% 52W Range23.31 - 70.96 Perf YTD21.35%
Dividend- P/FCF- EPS past 5Y23.90% ROI2.10% 52W High-6.85% Beta1.90
Dividend %- Quick Ratio9.30 Sales past 5Y39.10% Gross Margin59.50% 52W Low183.57% ATR2.82
Employees600 Current Ratio9.70 Sales Q/Q10.80% Oper. Margin-65.20% RSI (14)61.25 Volatility4.36% 4.90%
OptionableYes Debt/Eq0.00 EPS Q/Q3.90% Profit Margin-33.60% Rel Volume0.31 Prev Close66.76
ShortableYes LT Debt/Eq0.37 EarningsNov 05 AMC Payout- Avg Volume581.26K Price66.10
Recom2.80 SMA206.27% SMA5017.70% SMA20047.25% Volume179,741 Change-0.99%
Nov-17-20Upgrade Wells Fargo Underweight → Equal Weight $68
Oct-08-20Downgrade JP Morgan Neutral → Underweight $50
Jun-15-20Initiated Jefferies Hold $44
Mar-05-20Initiated Citigroup Sell $40
Feb-28-20Downgrade JP Morgan Overweight → Neutral $55
Jan-06-20Upgrade Berenberg Hold → Buy $60 → $65
Dec-12-19Downgrade Wells Fargo Outperform → Underperform
Sep-30-19Downgrade BofA/Merrill Buy → Underperform
Mar-08-19Initiated BTIG Research Neutral
Aug-30-18Initiated Berenberg Hold $57
Aug-29-18Upgrade JP Morgan Neutral → Overweight
Aug-03-18Reiterated Stifel Hold $32 → $35
Jun-21-18Downgrade JP Morgan Overweight → Neutral
Apr-13-18Downgrade Stifel Buy → Hold $39 → $32
Mar-01-18Reiterated Cantor Fitzgerald Buy $48 → $43
Mar-02-17Reiterated Cantor Fitzgerald Overweight $45 → $54
Jan-06-17Upgrade Stifel Hold → Buy $42 → $45
Oct-27-16Initiated Wells Fargo Outperform
Aug-02-16Reiterated Cantor Fitzgerald Buy $35 → $41
Jun-03-16Initiated Cantor Fitzgerald Buy $35
Nov-11-20 04:15PM  
Nov-10-20 04:46PM  
Nov-05-20 08:00PM  
Oct-29-20 12:34PM  
Oct-15-20 07:00AM  
Oct-14-20 10:13PM  
Oct-09-20 10:08AM  
Sep-29-20 08:05AM  
Sep-24-20 06:30AM  
Sep-14-20 07:05AM  
Sep-10-20 09:30AM  
Sep-09-20 04:20PM  
Sep-08-20 04:45PM  
Sep-05-20 11:32AM  
Sep-04-20 07:00AM  
Aug-31-20 08:00AM  
Aug-18-20 05:48PM  
Aug-12-20 07:10AM  
Aug-10-20 01:25PM  
Aug-06-20 09:00PM  
Jul-30-20 12:33PM  
Jul-20-20 07:00AM  
Jun-28-20 05:43PM  
Jun-18-20 07:43AM  
Jun-09-20 06:30PM  
Jun-08-20 10:42PM  
Jun-06-20 11:31AM  
Jun-03-20 11:19PM  
Jun-02-20 04:30PM  
May-15-20 08:00AM  
May-09-20 11:01AM  
May-08-20 08:50AM  
May-07-20 08:40PM  
Apr-21-20 08:30AM  
Apr-09-20 09:00AM  
Apr-08-20 08:48PM  
Mar-28-20 11:30AM  
Mar-24-20 09:00AM  
Mar-10-20 09:19AM  
Mar-09-20 07:02PM  
Mar-02-20 08:37AM  
Feb-27-20 04:15PM  
Feb-20-20 12:31PM  
Feb-07-20 10:52AM  
Feb-06-20 04:15PM  
Feb-04-20 07:57AM  
Jan-22-20 07:51AM  
Jan-03-20 07:15AM  
Dec-17-19 07:20AM  
Dec-14-19 09:43PM  
Dec-13-19 04:50PM  
Dec-06-19 11:31AM  
Nov-21-19 08:43AM  
Nov-20-19 04:15PM  
Nov-11-19 12:07PM  
Nov-08-19 09:08AM  
Nov-06-19 07:45PM  
Oct-30-19 04:15PM  
Oct-29-19 01:57PM  
Oct-22-19 04:15PM  
Oct-10-19 07:00AM  
Oct-09-19 04:15PM  
Oct-08-19 04:15PM  
Sep-26-19 09:52AM  
Sep-19-19 12:51PM  
Sep-13-19 07:00AM  
Sep-08-19 02:00PM  
Sep-06-19 09:31AM  
Aug-27-19 04:15PM  
Aug-14-19 08:15AM  
Aug-13-19 12:32PM  
Aug-12-19 07:40AM  
Aug-08-19 02:25PM  
Aug-07-19 07:25PM  
Jul-31-19 04:20PM  
Jul-30-19 10:59AM  
Jul-29-19 08:39AM  
Jul-22-19 07:00AM  
Jul-04-19 12:44PM  
Jun-27-19 04:15PM  
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; iDose Travoprost, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication; and MicroShunt, an ab-externo device for treatment of open-angle glaucoma. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was founded in 1998 and is headquartered in San Clemente, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Burns Thomas WilliamChief Executive OfficerMay 26Option Exercise3.98207,447824,602513,336May 27 08:10 PM
Burns Thomas WilliamChief Executive OfficerMay 26Sale39.23207,4478,137,527305,889May 27 08:10 PM
Burns Thomas WilliamChief Executive OfficerMay 20Option Exercise3.984001,590306,289May 22 07:23 PM
Burns Thomas WilliamChief Executive OfficerMay 20Sale38.0540015,221305,889May 22 07:23 PM
Burns Thomas WilliamChief Executive OfficerFeb 28Option Exercise5.59212,5961,188,419272,499Mar 02 07:24 PM
Gilliam Joseph ECFO, SVP Corporate DevelopmentFeb 12Option Exercise41.693,750156,33851,278Feb 14 04:31 PM
Gilliam Joseph ECFO, SVP Corporate DevelopmentFeb 12Sale68.503,750256,87547,528Feb 14 04:31 PM
Burns Thomas WilliamChief Executive OfficerDec 20Option Exercise3.9810,00039,75058,807Dec 23 07:07 PM
Burns Thomas WilliamChief Executive OfficerDec 09Option Exercise3.703,58313,25748,807Dec 11 07:39 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.